Premium
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
Author(s) -
Zuberbier Torsten,
Abdul Latiff Amir Hamzah,
Abuzakouk Mohamed,
Aquilina Susan,
Asero Riccardo,
Baker Diane,
BallmerWeber Barbara,
Bangert Christine,
BenShoshan Moshe,
Bernstein Jonathan A.,
BindslevJensen Carsten,
Brockow Knut,
Brzoza Ze,
Chong Neto Herberto Jose,
Church Martin K.,
Criado Paulo R.,
Danilycheva Inna V.,
Dressler Corinna,
Ensina Luis Felipe,
Fonacier Luz,
Gaskins Matthew,
Gáspár Krisztian,
Gelincik Aslı,
GiménezArnau Ana,
Godse Kiran,
Gonçalo Margarida,
Grattan Clive,
Grosber Martine,
Hamelmann Eckard,
Hébert Jacques,
Hide Michihiro,
Kaplan Allen,
Kapp Alexander,
Kessel Aharon,
Kocatürk Emek,
Kulthanan Kanokvalai,
LarenasLinnemann Désirée,
Lauerma Antti,
Leslie Tabi A.,
Magerl Markus,
Makris Michael,
Meshkova Raisa Y.,
Metz Martin,
Micallef Daniel,
Mortz Charlotte G.,
Nast Alexander,
OudeElberink Hanneke,
Pawankar Ruby,
Pigatto Paolo D.,
Ratti Sisa Hector,
Rojo Gutiérrez María Isabel,
Saini Sarbjit S.,
SchmidGrendelmeier Peter,
Sekerel Bulent E.,
Siebenhaar Frank,
Siiskonen Hanna,
Soria Angele,
StaubachRenz Petra,
Stingeni Luca,
Sussman Gordon,
Szegedi Andrea,
Thomsen Simon Francis,
Vadasz Zahava,
Vestergaard Christian,
Wedi Bettina,
Zhao Zuotao,
Maurer Marcus
Publication year - 2022
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/all.15090
Subject(s) - guideline , medicine , angioedema , omalizumab , excellence , grading (engineering) , european union , allergy , clinical immunology , medline , dermatology , family medicine , immunology , pathology , immunoglobulin e , civil engineering , business , political science , antibody , law , economic policy , engineering
Abstract This update and revision of the international guideline for urticaria was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the Global Allergy and Asthma European Network (GA²LEN) and its Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs), the European Dermatology Forum (EDF; EuroGuiDerm), and the Asia Pacific Association of Allergy, Asthma and Clinical Immunology with the participation of 64 delegates of 50 national and international societies and from 31 countries. The consensus conference was held on 3 December 2020. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell–driven disease that presents with wheals, angioedema, or both. The lifetime prevalence for acute urticaria is approximately 20%. Chronic spontaneous or inducible urticaria is disabling, impairs quality of life, and affects performance at work and school. This updated version of the international guideline for urticaria covers the definition and classification of urticaria and outlines expert‐guided and evidence‐based diagnostic and therapeutic approaches for the different subtypes of urticaria.